Enhanced flow in small-world networks.

Phys Rev Lett

Departamento de Física, Universidade Federal do Ceará, 60451-970 Fortaleza, Ceará, Brazil.

Published: April 2014

The proper addition of shortcuts to a regular substrate can lead to the formation of a complex network with a highly efficient structure for navigation [J. M. Kleinberg, Nature 406, 845 (2000)]. Here we show that enhanced flow properties can also be observed in these small-world topologies. Precisely, our model is a network built from an underlying regular lattice over which long-range connections are randomly added according to the probability, Pij ∼ r−α ij , where rij is the Manhattan distance between nodes i and j, and the exponent α is a controlling parameter. The mean two-point global conductance of the system is computed by considering that each link has a local conductance given by gij ∝ r−C ij , where C determines the extent of the geographical limitations (costs) on the long-range connections. Our results show that the best flow conditions are obtained for C = 0 with α = 0, while for C ≫ 1 the overall conductance always increases with α. For C ≈ 1, α = d becomes the optimal exponent, where d is the topological dimension of the substrate. Interestingly, this exponent is identical to the one obtained for optimal navigation in small-world networks using decentralized algorithms.

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.112.148701DOI Listing

Publication Analysis

Top Keywords

enhanced flow
8
small-world networks
8
long-range connections
8
flow small-world
4
networks proper
4
proper addition
4
addition shortcuts
4
shortcuts regular
4
regular substrate
4
substrate lead
4

Similar Publications

Background: Acute lung injury (ALI) significantly impacts the survival rates in intensive care units (ICU). Releasing a lot of pro-inflammatory mediators during the progression of the disease is a core feature of ALI, which may lead to uncontrolled inflammation and further damages the tissues and organs of patients. This study explores the potential therapeutic mechanisms of Dexmedetomidine (Dex) in ALI.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear.

Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases.

View Article and Find Full Text PDF

Objective: Gastric cancer (GC) is a globally common cancer characterized by high incidence and mortality worldwide. Advances in the molecular understanding of GC provide promising targets for GC diagnosis and therapy. Long non-coding RNAs (lncRNAs) and their downstream regulators are regarded to be implicated in the progression of multiple types of malignancies.

View Article and Find Full Text PDF

Background: To investigate SCL/TAL 1 interrupting locus ()'s role and prognostic significance in lung adenocarcinoma (LUAD) progression, we examined and E2 promoter binding factor 1 (E2F1) expression and their impacts on LUAD prognosis using Gene Expression Profiling Interactive Analysis (GEPIA).

Methods: Functional assays including CCK-8, wound-healing, 5-ethynyl-2-deoxyuridine (EdU), Transwell assays, and flow cytometry, elucidated and E2F1's effects on cell viability, proliferation, apoptosis, and migration. Gene set enrichment analysis (GSEA) identified potential pathways, while metabolic assays assessed glucose metabolism.

View Article and Find Full Text PDF

Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!